Vincristine |
Catalog No.GC38410
One-Click Copy Product Info
|
Vincristine is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32μM in a cell-free assay. Vincristine can induces apoptosis.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 57-22-7
Sample solution is provided at 25 µL, 10mM.
Vincristine is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32μM in a cell-free assay. Vincristine can induces apoptosis[1].
Vincristine (100nM; 48h) induces distinct death programs in primary ALL cells depending on cell cycle phase, and cells in G1 are susceptible to perturbation of interphase microtubules[2].Vincristine (5nM; 4, 8, 24h) triggers a cascade of axon pathology, causing mitochondrial dysfunction that leads to elevated axonal ROS levels and SARM1-dependent axon degeneration[3].Vincristine (0.3-10nM; 48h) and SAHA on T cell leukemic cells resulted in a change in microtubule dynamics contributing to M phase arrest followed by induction of the apoptotic pathway[4].
Vincristine (Pre: <10μg or 0.5mg/kg; Post: 10μg; ip; 25d) causes swelling and redness of the injected paw as well as a strong dose-dependent infiltration of immune cells to the site of injection. Consistent with the neuro-inflammatory signature, mechanical allodynia was decreased in mice lacking Tlr4, as well as in mice treated with minocycline[5].Vincristine (3mg/kg; iv; 1 time) administrated by a single i.p. injection to mice bearing bilateral subcutaneous xenografts Rh12 or Rh18, induces mean growth delay of >120 and >52day, and repopulating fractions of 0.06% and 5%, respectively[6].
References:
[1].Jordan MA, Himes RH, Wilson L. Comparison of the effects of vinblastine, Vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro. Cancer Res. 1985 Jun;45(6):2741-7.
[2].Kothari A, Hittelman W N, Chambers T C. Cell cycle–dependent mechanisms underlie Vincristine-induced death of primary acute lymphoblastic leukemia cells[J]. Cancer research, 2016, 76(12): 3553-3561.
[3].Gomez-Deza J, Slavutsky A L, Nebiyou M, et al. Local production of reactive oxygen species drives Vincristine-induced axon degeneration[J]. Cell Death & Disease, 2023, 14(12): 807.
[4].Chao MW, Lai MJ, Liou JP, Chang YL, Wang JC, Pan SL, Teng CM. The synergic effect of Vincristine and vorinostat in leukemia in vitro and in vivo. J Hematol Oncol. 2015 Jul 10;8:82.
[5].Starobova H, Mueller A, Allavena R, et al. Minocycline prevents the development of mechanical allodynia in mouse models of Vincristine-induced peripheral neuropathy[J]. Frontiers in Neuroscience, 2019, 13: 653.
[6].Baguley BC, Holdaway KM, Thomsen LL, Zhuang L, Zwi LJ. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer. 1991;27(4):482-7.
| Cell experiment [1]: | |
Cell lines | ALL-2 cells |
Preparation Method | The ALL-2 cells in either G1 or G2/M phases were treated with vehicle (0.1% DMSO) or 100nM Vincristine, harvested at specific times, and DNA content analyzed. |
Reaction Conditions | 100nM; 48h |
Applications | When treated with Vincristine, cells underwent M phase arrest, with 86.4% cells having 4N DNA content within 8h of Vincristine treatment, and by 48h, 50% of cells had <2N DNA content. |
| Animal experiment [2]: | |
Animal models | Vincristine-induced peripheral neuropathy (VIPN) Model |
Preparation Method | Vincristine (<10μg; ip; or 0.5mg/kg; ip) or vehicle (PBS; ip) were administered for five consecutive days, with 2 days break, followed by another five consecutive injections. The highest Vincristine dose (10μg; ip) was administered for four consecutive days, followed by 5 days break and another two injections. Minocycline (25mg/kg; ip) was administered once daily, 3 days before Vincristine administration, and then with each Vincristine injection. |
Dosage form | 1-12 days: <10μg or 0.5mg/kg; 12-25 days: 10μg; ip; 25 days |
Applications | Injection of Vincristine causes swelling and redness of the injected paw as well as a strong dose-dependent infiltration of immune cells to the site of injection. Consistent with the neuro-inflammatory signature, mechanical allodynia was decreased in mice lacking Tlr4, as well as in mice treated with minocycline. |
References: | |
| Cas No. | 57-22-7 | SDF | |
| Canonical SMILES | CC[C@@]1(C=CCN2CC3)[C@@]2([H])[C@@]3(C4=CC([C@](C5=C6C7=CC=CC=C7N5)(C[C@](C[C@](CC)(O)C8)([H])C[N@@]8CC6)C(OC)=O)=C(OC)C=C4N9C=O)[C@]9([H])[C@](C(OC)=O)(O)[C@@H]1OC(C)=O | ||
| Formula | C46H56N4O10 | M.Wt | 824.96 |
| Solubility | Soluble in DMSO | Storage | Store at -20°C, protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.2122 mL | 6.0609 mL | 12.1218 mL |
| 5 mM | 242.4 μL | 1.2122 mL | 2.4244 mL |
| 10 mM | 121.2 μL | 606.1 μL | 1.2122 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 25 reference(s) in Google Scholar.)